Phase 2 N=10 SP16 Inflammatory Response Inhibition Trial
Myocardial Infarction · Inflammation
Primary: Area Under the Curve (AUC) for C-reactive Protein (CRP) — 133 mg*day/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=55 Effect IV Ibuprofen and Inflammatory Responses
Gallbladder Disease
Primary: Stress Response Inflammation Markers :Cortisol and C Reactive Protein (CRP) — 173.6; 289.5; 17; 17 pg/mL
N/A N=119 Exercise and Inflammation in the Elderly
Inflammation · Insulin Sensitivity
Primary: Insulin Sensitivity — 50.2; 40.7; 57.5; 42.3 μmol/kgFFM/min
N/A N=15 Human Biological Responses to Low Level Ozone
Environmental Exposure · Nasal Inflammation
Primary: Change in % Polymorphonuclear Leukocytes (PMN) in Nasal Lavage Fluid Immediately Post-Exposure From Baseline — -1.02; -6.8 percent PMNs in nasal lavage fluid
N/A N=100 Inflammation and the Metabolic Syndrome in Humans
Metabolic Syndrome X
Primary: The Primary Outcome Measure is Plasma Levels of TNF Alpha. — 507 ng/mL
Phase 1 N=70 Inflammatory Markers in Trauma Patient Outcomes
Polytrauma
Primary: Length of Hospital Stay — 7; 8 days — p==0.275
N/A N=141 Anti-inflammatory Effect of Therapeutic Hypothermia in Out-hospital Cardiac Arrest Patients With Cardiogenic Shock
Cardiac Arrest
Primary: Survival Rate - Number of Participants Alive — 55; 20; 32; 34 Participants — p=<0.001
Phase 2 N=56 Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants
Complication Due to Immunization
Primary: The Change in the Number of CRE (Extracted From Printed Monitoring Tracings Compared to Noted Nurses' Surveillance) Following the First Dose of Pentavalent Vaccine in…
Phase 2 N=20 An Inflammatory Challenge Using Endotoxin
Alcohol Use Disorder · Inflammatory Response · Craving
Primary: Cue-induced Craving — 4.5004; 7.9081; 4.5004; 5.6178 score on a scale — p=0.036
N/A N=20 Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of Anti-inflammatory Effects
Healthy
Primary: Toll-like Receptor 4 Expression Pre- and Post-Treatment — 12.37; 6.36 % tlr expression (monocytes)
N/A N=25 Diet and Systemic Inflammation
Low-grade Chronic Inflammation · Intestinal Permeability · Type 2 Diabetes Mellitus
Primary: Fasting Plasma C-reactive Protein — 0.91; 1.07; 1.67; 1.09 mg/L — p=0.403
N/A N=35 Vitreous Inflammation in Standard and Heavy Silicone Oil
Vitreous Inflammation
Primary: Vitreous Prostaglandin E2 Levels — 369.38; 869.16 pg/mL
N/A N=39 Anti-Inflammatory Treatment of Schizophrenia
Schizophrenia
Primary: Change in Persistent Positive Symptoms — 13; 14; 14; 14 units on a scale
N/A N=60 Leukocyte Function in Asthma and COPD
Asthma · COPD · Emphysema
Primary: Total Number of Inflammatory Cells Recovered in Sputum — 2.3; 2.1; 1.9; 5.2 10^6 cells/ml — p=0.1
N/A N=99 Inflammatory Abnormalities in Muscle After Stroke: Effects of Exercise
Stroke · Inflammation
Primary: Cardiovascular Fitness (VO2 Peak) — 15.9; 16.6; 21.3; 17.5 ml/kg/min — p=0.001
Phase 3 N=36 The Innate Central Nervous System Immune Response to an Experimental Immune Challenge in People With Fibromyalgia
Fibromyalgia
Primary: Change in Ratio of Choline/ Creatine (CHO/CR) in the Brain From Baseline to 3 Hrs Post-endotoxin Administration — -.0021; -.0058 ratio
N/A N=44 Challenging the Inflammatory Response System in Insomnia Disorder
Insomnia
Primary: Inflammatory Response to Physiological Challenge- Change in Plasma Levels of IL-6 — 1.5013; 2.1626; 2.5911; 2.7269 pg/mL
N/A N=17 Regulation of the Release of Inflammatory Mediators From Lung Macrophages.
COPD · Chronic Bronchitis · Emphysema
Primary: Macrophage Activation, TNF-a — 6.1; 3.8; 2.6 ng/ml — p=0.05
Phase 1 N=57 Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo
Healthy
Primary: Total Cell Count of Neutrophils in Bronchoalveolar Lavage (BAL) Fluid After 24 Hours of the Segmental Lipopolysaccharide (LPS) Challenge — 687.02; 872.61…
Phase 3 N=123 Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
Vascular Inflammation · Atherosclerotic Cardiovascular Disease
Primary: Change in Arterial Inflammation — 0.03; 0.20 percent change
Phase 3 N=46 Cytokine Removal in Cardiopulmonary Bypass Patients
Elective Cardiac Surgical Interventions
Primary: IL-6 — 0; 0; 0; 0 pg/ml
N/A N=21 Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation
Inflammatory Responses
Primary: Change in C Reactive Protein (CRP) — 17.2; 17.1 mg/L
N/A N=128 Inflammation and the Heart
Rheumatoid Arthritis
Primary: Left Ventricular Mass Indexed to BSA, g/m^2 — 43.8; 42.2 g/m^2
Phase 3 N=125 Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation
Cardiovascular Disease · Inflammation
Primary: Mean Concentrations of Inflammatory Markers (TNF-alpha and IL-6) Following 5 Months of Treatment — 1.4; 1.3; 1.4; 1.5 pg/mL
N/A N=10 Anti-inflammatory Effects of the Fiber
Type 2 Diabetes
Primary: Peak Change in From Baseline in Reactive Oxygen Species (ROS) Generation — 224; 167 percentage of change
N/A N=74 Lipids, Inflammation, and CV Risk in RA
Rheumatoid Arthritis · Cardiovascular Disease
Primary: Coronary Flow Reserve — 2.65 ratio
Phase 2 N=94 Inflammation and Coronary Endothelial Function
Coronary Artery Disease
Primary: Percent Change in Coronary Cross Sectional Area (CSA) From Rest to That During Isometric Handgrip Exercise (IHE) — -1.70; 2.71; -0.39; 2.04 Percent change from rest…
N/A N=39 Inflammation and Corticosteroid Responsiveness in Severe Asthma
Asthma
Primary: Lung Function FEV1 — 84.9; 59.9 % of predicted — p=0.001
Phase 3 N=20 Sitagliptin Therapy and Kinetics of Inflammatory Markers
Type 2 Diabetes Mellitus
Primary: Measurement of C-reactive Protein Production Rate With Stable Isotope During Postprandial Period
N/A N=20 Acupuncture for Reduction of Inflammation
Thyroid or Parathyroid Surgery
Primary: Reduced Pain Medication Requirement — 5.43; 7.36 mg of Morphine